Lexicon Pharmaceuticals Inc (LXRX, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas. Lexicon Pharmaceuticals Inc has a market cap of $776.433 million; its shares were traded at around $7.33 with and P/S ratio of 9.81.
For the last quarter Lexicon Pharmaceuticals Inc reported a revenue of $17.1 million, compared with the revenue of $33.05 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $63.2 million, a decrease of 30% from the previous year. For the last five years Lexicon Pharmaceuticals Inc had an average revenue growth rate of 79.2% a year.
The reported loss per diluted share was $1.14 for the year, compared with the loss per share of $1.31 in the previous year. The Lexicon Pharmaceuticals Inc had an operating margin of -163.39%, compared with the operating margin of -148.98% a year before. The 10-year historical median operating margin of Lexicon Pharmaceuticals Inc is -608.15%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Lexicon Pharmaceuticals Inc has the cash and cash equivalents of $160.1 million, compared with $61.7 million in the previous year. The company had no long term debt, compared with $231.6 million in the previous year. Lexicon Pharmaceuticals Inc has a financial strength rank of 2 (out of 10).
At the current stock price of $7.33, Lexicon Pharmaceuticals Inc is traded at 60.6% discount to its historical median P/S valuation band of $18.60. The P/S ratio of the stock is 9.81, while the historical median P/S ratio is 24.91. The stock lost 13.56% during the past 12 months.
For the complete 20-year historical financial data of LXRX, click here.
